

EDITORIAL

Definitions, guidelines and opinions: the white, the black and the grey



Luciano Gattinoni*

© 2024 The Author(s)

Due to demographic reasons, I have had the opportunity to participate in all the international consensus conferences, up to Berlin [1], for the definition of acute respiratory distress syndrome (ARDS) and the development of guidelines for its management. The current tendency is to simplify both the definition and the management approach, primarily focussing on oxygenation or haemoglobin oxygen saturation [2], whilst other physiological variables, as respiratory mechanics or haemodynamics, are downplayed or ignored. It is, therefore, worthwhile to question the real value of guidelines in defining and managing ARDS, especially today when two leading societies have issued markedly different recommendations for three key aspects: positive end-expiratory pressure (PEEP) selection, venovenous extracorporeal membrane oxygenation (VV-ECMO) indications, and use of neuromuscular blockade [3, 4]. Before addressing these issues, it is crucial to reflect on the value of guidelines in managing syndromes such as ARDS, which is a collection of signs and symptoms with various causes and not a single disease.

Guidelines are a collaborative effort by experts who, through a combination of scientific evidence and personal opinions, produce recommendations. The generation of evidence relies heavily on the analysis of randomised clinical trials (RCTs), and methods like the Delphi technique for consensus building, culminating in a “democratic” vote. Consequently, the limitations of clinical trials become the limitations of the evidence, and the democratic process generates the majority’s opinion, not necessarily the truth. The major limitations of RCTs in providing scientific evidence are clear: they typically include a small fraction of screened patients

(about 10%) and overlook fundamental aspects of medicine such as patient history, age, prior health status, and comorbidities, which are theoretically neutralised by randomisation. Identical entry criteria in sepsis studies led to mortality rates ranging from 25% to 60%, in supposedly similar populations [5]. Unfortunately, current thinking often ignores these limitations, and RCTs and meta-analyses remains “dogmatic”. The production of “evidence” has become a profession and an industry, characterised by rising costs, and rules dictated by professional trialists. Consequently, common clinical sense is sometimes lost.

One of the principles of statistical analysis is to exclude prior experiences, placing expert opinion at the lowest level of the evidence hierarchy. However (as you may have guessed, I am not a statistician!), I humbly believe that all our experience is nothing else than a “post-hoc analysis” and, most of decisions in our lives, including medical ones, are based on previous experiences. This highlights the limitations of relying solely on RCTs for guideline development. However, the “recent evidence” from guidelines suggests that opinions frequently outweigh the evidence provided by RCTs [6].

The recent differences in the guidelines produced by the American Thoracic Society (ATS) and the European Society of Intensive Care Medicine (ESICM) clearly underline these issues. I will limit my discussion to PEEP selection and VV-ECMO indication. When two expert panels, sharing 33% of participants and the same evidence, reach different conclusions, it suggests that opinions outweigh evidence. In two editorials published in this issue of Intensive Care Medicine [7, 8], the authors of the guidelines attempt to persuade readers that the differences are more apparent than substantial. However, for the “average” reader, the absence of a PEEP recommendation for all ARDS patients [4], or the

*Correspondence: gattinoniluciano@gmail.com
Department of Anesthesiology, University Medical Centre Göttingen,
Robert Koch Straße 40, 37075 Göttingen, Germany

recommendation to use high PEEP in moderate to severe ARDS [3] is substantially different.

In real life, despite these contradictory recommendations, the trial results indicate that a general population benefits equally from a PEEP around 7 cmH₂O and PEEP around 12 cmH₂O. This suggests that in a population (not in a single individual), the risk/benefit ratio of atelectrauma (lower PEEP) is similar to the risk/benefits of volutrauma (higher PEEP) [9–11]. But, mortality increases with PEEP over 15 cmH₂O, suggesting higher volutrauma risks in a significant patient subset [12]. From this simple “evidence”, a complicated methodological approach led ESICM to conclude, and I paraphrase: “choose the PEEP you prefer” and the ATS: “you should use higher PEEP” (following the PEEP/FiO₂ table, which recommend, as an example, a PEEP of 16 when the set FiO₂ is 40%) [11]. Similar reasoning may be applied to the use of neuromuscular agents.

The recommendation on extracorporeal support is a curious one and illustrates this issue further. From the Zapol’s study to the EOLIA trial, classic RCTs failed to show a statistical benefit for VV-ECMO in severe ARDS. However, whilst initial trials led to a discontinuation of ECMO use, the EOLIA trial, despite being stopped for futility, was seen as “the positive amongst the negatives” [13, 14]. This reflects a shift in opinion rather than evidence, underscoring the influence of contemporary views on the use of ECMO. Although I am personally convinced that ECMO is a powerful tool to buy time until disease resolution and this is self-evident in clinical practise. In this framework, with similar levels of evidence (negative trial!), the ESICM strongly recommended against extracorporeal CO₂ removal and strongly recommended in favour of ECMO when in accordance with the EOLIA protocol. In contrast, the ATS opted for a more prudent recommendation. Once again, the evidence is largely overcome by the panel opinion. In summary, the recent guidelines for ARDS treatment from ATS and ESICM cast reasonable concerns about their usefulness and applicability.

Therefore, we may ask ourselves how to proceed to select the most adequate treatment for a given patient. Before doing so, it is interesting to consider that the ARDS approach currently undertaken by the intensivists is the exact opposite to that of oncologists. Indeed, we began with an “obsessive” characterisation (mechanics, haemodynamic, gas-exchange, etc.) of individual patients (personalization), but later we shifted in a U-turn towards studying population behaviour through randomised studies, whilst oncologists moved from RCTs towards a more personalised approach (focussing on individual receptors and specific patient characteristics). My belief is that in the intensive care practise, which

focuses on symptomatic treatment to sustain life until the underlying disease is resolved, the most logical approach is to identify the mechanisms at play in a given patient. For example, ventilatory treatment in ARDS cannot be rationally applied without understanding lung volumes and esophageal pressures, which are crucial for estimating lung strain and stress. Whilst guidelines can be useful in certain situations, their creation and application should not replace medical reasoning, which is aimed at addressing individual patient needs rather than population-wide issues.

Funding

Open Access funding enabled and organized by Projekt DEAL.

Declarations

Conflicts of interest

None.

Open Access

This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 21 March 2024 Accepted: 23 March 2024

Published online: 06 May 2024

References

1. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS (2012) Acute respiratory distress syndrome: the Berlin definition. *JAMA* 307:2526–2533. <https://doi.org/10.1001/jama.2012.5669>
2. Matthay MA, Arabi Y, Arroliga AC, Bernard G, Bersten AD et al (2024) New global definition of acute respiratory distress syndrome. *Am J Respir Crit Care Med* 209:37–47. <https://doi.org/10.1164/rccm.202303-0558WS>
3. Qadir N, Sahetya S, Munshi L, Summers C, Abrams D et al (2024) An update on management of adult patients with acute respiratory distress syndrome: an official American Thoracic Society clinical practice guideline. *Am J Respir Crit Care Med* 209:24–36. <https://doi.org/10.1164/rccm.202311-2011ST>
4. Grasselli G, Calfee CS, Camporota L, Poole D, Amato MBP et al (2023) European guidelines on acute respiratory distress syndrome: a definition, phenotyping and respiratory support strategies. *Intensive Care Med* 49:727–759. <https://doi.org/10.1007/s00134-023-07050-7>
5. Gattinoni L, Ranieri VM, Pasenti A (2015) Sepsis: need for defining severity. *Intensive Care Med* 41:551–552. <https://doi.org/10.1007/s00134-014-3598-8>

-
6. Gattinoni L, Citerio G, Slutsky A (2023) Back to the future: ARDS guidelines, evidence, and opinions. *Intensive Care Med* 49:1226–1228. <https://doi.org/10.1007/s00134-023-07183-9>
 7. Camporota L, Calfee CS, Grasselli G (2024) ARDS guidelines: ocean apart of rivers that merge. *Intensive Care Med* (in press)
 8. Sahetya S, Rochweg B, Fan E (2024) Global guidelines require global collaboration: the ATS view. *Intensive Care Med*. <https://doi.org/10.1007/s00134-024-07431-6>
 9. Mercat A, Richard JC, Vielle B, Jaber S, Osman D et al (2008) Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. *JAMA* 299:646–655. <https://doi.org/10.1001/jama.299.6.646>
 10. Meade MO, Cook DJ, Guyatt GH, Slutsky AS, Arabi YM et al (2008) Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. *JAMA* 299:637–645. <https://doi.org/10.1001/jama.299.6.637>
 11. Brower RG, Lanken PN, MacIntyre N, Matthay MA, Morris A et al (2004) Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. *N Engl J Med* 351:327–336. <https://doi.org/10.1056/NEJMoa032193>
 12. Cavalcanti AB, Suzumura ÉA, Laranjeira LN, Paisani DM, Damiani LP (2017) Effect of lung recruitment and titrated positive end-expiratory pressure (PEEP) vs low PEEP on mortality in patients with acute respiratory distress syndrome: a randomized clinical trial. *JAMA* 318:1335–1345. <https://doi.org/10.1001/jama.2017.14171>
 13. Zapol WM, Snider MT, Hill JD, Fallat RJ, Bartlett RH (1979) Extracorporeal membrane oxygenation in severe acute respiratory failure. A randomized prospective study. *JAMA* 242:2193–2196. <https://doi.org/10.1001/jama.242.20.2193>
 14. Combes A, Hajage D, Capellier G, Demoule A, Lavoué S et al (2018) Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. *N Engl J Med* 378:1965–1975. <https://doi.org/10.1056/NEJMo a1800385>